公开(公告)号：US20240002391A1

公开(公告)日：2024-01-04

申请号：US18340543

申请日：2023-06-23

Applicant: BioSplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Chi Ching Mak ,  Lewis Daniel Turner ,  Brian Joseph Hofilena ,  Ramkrishna Reddy Vakiti ,  Brian Walter Eastman ,  David Mark Wallace

IPC: C07D487/04 ,  C07D519/00

CPC classification number: C07D487/04 ,  C07D519/00

Abstract: 4-Alkoxypyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-alkoxypyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

公开(公告)号：US11548872B2

公开(公告)日：2023-01-10

申请号：US17155577

申请日：2021-01-22

Applicant: BioSplice Therapeutics, Inc.

Inventor： Sunil Kumar KC ,  Chi Ching Mak ,  Brian Walter Eastman ,  Jianguo Cao ,  Venkataiah Bollu ,  Gopi Kumar Mittapalli ,  Chandramouli Chiruta

IPC: A61K31/4725 ,  C07D401/14 ,  C07D471/10 ,  C07D417/04 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D487/08 ,  C07D401/04 ,  C07D491/048 ,  C07D417/14 ,  C07D487/04 ,  C07D471/08

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US20230312605A1

公开(公告)日：2023-10-05

申请号：US17964489

申请日：2022-10-12

Applicant: BioSplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Sunil Kumar KC ,  Chi Ching Mak ,  Brian Joseph Hofilena ,  Lewis Daniel Turner ,  Brian Walter Eastman ,  Ramkrishna Reddy Vakiti ,  Joseph Timothy Marakovits

IPC: C07D519/00 ,  C07D487/04

CPC classification number: C07D519/00 ,  C07D487/04 ,  C07B2200/05

Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer’s disease, diabetes, viral infections, and osteoarthritis).

公开(公告)号：US20230167133A1

公开(公告)日：2023-06-01

申请号：US17964470

申请日：2022-10-12

Applicant: BioSplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Sunil Kumar KC ,  Chi Ching Mak ,  Brian Joseph Hofilena ,  Chandramouli Chiruta ,  Ramkrishna Reddy Vakiti ,  Brian Walter Eastman ,  Joseph Timothy Marakovits ,  Lewis Daniel Turner

IPC: C07D519/00 ,  C07D487/04

CPC classification number: C07D519/00 ,  C07D487/04 ,  C07B2200/05

Abstract: 7H-Pyrrolo[2,3-d]pyrimidine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 7H-pyrrolo[2,3-d]pyrimidine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

公开(公告)号：US20220402921A1

公开(公告)日：2022-12-22

申请号：US17138098

申请日：2020-12-30

Applicant: BioSplice Therapeutics, Inc.

Inventor： Sunil Kumar KC ,  Chi Ching Mak ,  Gopi Kumar Mittapalli ,  Brian Joseph Hofilena ,  Brian Walter Eastman ,  Jianguo Cao ,  Chandramouli Chiruta ,  Venkataiah Bollu

IPC: C07D487/04 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  A61P19/04

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

公开(公告)号：US20230286945A1

公开(公告)日：2023-09-14

申请号：US17990133

申请日：2022-11-18

Applicant: Biosplice Therapeutics, Inc.

Inventor： Sunil Kumar KC ,  Chi Ching Mak ,  Brian Walter Eastman ,  Jianguo Cao ,  Venkataiah Bollu ,  Gopi Kumar Mittapalli ,  Chandramouli Chiruta

IPC: C07D401/14 ,  C07D471/10 ,  C07D417/04 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D487/08 ,  C07D401/04 ,  C07D491/048 ,  C07D417/14 ,  C07D487/04 ,  C07D471/08

CPC classification number: C07D401/14 ,  C07D471/10 ,  C07D417/04 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D487/08 ,  C07D401/04 ,  C07D491/048 ,  C07D417/14 ,  C07D487/04 ,  C07D471/08

Abstract: Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

公开(公告)号：US20230192686A1

公开(公告)日：2023-06-22

申请号：US17964423

申请日：2022-10-12

Applicant: BioSplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Sunil Kumar KC ,  Chi Ching Mak ,  Brian Joseph Hofilena ,  Chandramouli Chiruta ,  Venkataiah Bollu ,  Md Sharif Al Asad ,  Brian Walter Eastman

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D471/04 ,  C07D519/00

Abstract: Pyrrolo[2,3-b]pyridine compound for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,3-b]pyridine compound or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

公开(公告)号：US12134625B2

公开(公告)日：2024-11-05

申请号：US17964489

申请日：2022-10-12

Applicant: BioSplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Sunil Kumar K C ,  Chi Ching Mak ,  Brian Joseph Hofilena ,  Lewis Daniel Turner ,  Brian Walter Eastman ,  Ramkrishna Reddy Vakiti ,  Joseph Timothy Marakovits

IPC: C07D519/00 ,  C07D487/04

Abstract: Pyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of pyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis).

公开(公告)号：US20240199649A1

公开(公告)日：2024-06-20

申请号：US18501307

申请日：2023-11-03

Applicant: Biosplice Therapeutics, Inc.

Inventor： Gopi Kumar Mittapalli ,  Chi Ching Mak ,  Lewis Daniel Turner ,  Ramkrishna Reddy Vakiti ,  Brian Walter Eastman ,  Brian Joseph Hofilena

IPC: C07D519/00 ,  C07B59/00

CPC classification number: C07D519/00 ,  C07B59/002 ,  C07B2200/05

Abstract: 4-Aminopyrrolo[2,1-f][1,2,4]triazine compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4-aminopyrrolo[2,1-f][1,2,4]triazine compounds or analogs thereof, in the treatment of disorders characterized by overexpression of DYRK1A (e.g., cancer, Down syndrome, Alzheimer's disease, diabetes, and osteoarthritis).

公开(公告)号：US11713320B2

公开(公告)日：2023-08-01

申请号：US17138098

申请日：2020-12-30

Applicant: BioSplice Therapeutics, Inc.

Inventor： Sunil Kumar Kc ,  Chi Ching Mak ,  Gopi Kumar Mittapalli ,  Brian Joseph Hofilena ,  Brian Walter Eastman ,  Jianguo Cao ,  Chandramouli Chiruta ,  Venkataiah Bollu

IPC: C07D487/04 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  A61P19/04 ,  A61P11/00 ,  A61P17/06 ,  A61P35/00

CPC classification number: C07D487/04 ,  A61P19/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  A61P11/00 ,  A61P17/06 ,  A61P35/00

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.